Tesofensine – 100 x 0.5mg Tablets

Tesofensine – 100 x 0.5mg Tablets

Contents: 100 x 0.5mg Tablets
Note: Strictly for research purposes only. Not for human consumption

🔬 Product Overview

Tesofensine is a potent research compound originally studied for neurodegenerative disorders and later observed to have strong appetite-suppressing and weight-modulating effects. It is classed as a triple monoamine reuptake inhibitor and has shown promise in early-stage trials for supporting fat loss mechanisms.

This listing is for researchers and laboratories only. It is not intended for human use.

📦 What’s Included

100 x 0.5mg tablets
Equivalent to a 100-day research supply
Premium-grade purity from trusted synthesis sources
Secure and discreet packaging
⚗️ Research Interest & Observed Benefits (in Laboratory Settings)

Appetite modulation through dopamine and serotonin regulation
Potential impact on fat metabolism and energy levels
May influence reward-centred eating behaviour
Neurochemical stimulation without direct stimulant action
💷 Why This Is a Long-Term Value

Other vendors typically offer just 30 tablets for £120+. Our 100-tablet research pack at £225 offers unmatched value and convenience for extended research:

🔬 100 days of data collection potential
💰 Over 60% savings vs short-term packs
📊 Ideal for full-cycle metabolic or behavioural research
⚠️ Important Notice

This product is sold strictly for laboratory research purposes. It is not intended for human consumption, therapeutic use, or dietary supplementation.

🔗 Tesofensine + Retatrutide in Research Settings

When co-administered in a research environment, Tesofensine may complement the effects of GLP-1 and GIP receptor agonists like Retatrutide by acting through alternative pathways:

Retatrutide: Hormonal appetite control & glucose regulation
Tesofensine: Central nervous system modulation & reward suppression
This multi-targeted model is of interest in studies exploring long-term weight regulation, energy expenditure, and behavioural adherence in obese or insulin-resistant models.
£200.00